<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="339">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04352400</url>
  </required_header>
  <id_info>
    <org_study_id>RACONA Nafamostat</org_study_id>
    <nct_id>NCT04352400</nct_id>
  </id_info>
  <brief_title>Efficacy of Nafamostat in Covid-19 Patients (RACONA Study)</brief_title>
  <acronym>RACONA</acronym>
  <official_title>RAndomized Clinical Trial in COvid19 Patients to Assess the Efficacy of the Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor NAfamostat (RACONA Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Padova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yokohama City University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Padova</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RACONA is a prospective trial that will test the hypothesis that nafamostat can lower lung
      function deterioration and need for intensive care admission in COVID-19 patients.

      Design: Adult hospitalized COVID-19 patients will be randomized in a prospective double-blind
      randomized placebo-controlled study to test the clinical efficacy of nafamostat mesylate
      (administered intravenously) on top of best standard of care.

      Primary outcome measures: the time-to-clinical improvement, defined as the time from
      randomization to an improvement of two points (from the status at randomization) on a seven
      category ordinal scale or live discharge from the hospital, whichever comes first.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: SARS-Cov-2 enters the lung cells by binding to ACE-2 and activating the protease
      TMPRSS2, which, therefore, can be a target for antiviral treatment. Accordingly, TMPRSS2
      inhibitors prevent SARS-CoV cell entry in vitro. The most potent such inhibitors, nafamostat
      is being used as anticoagulant and anti-pancreatitis agent, and is approved for the treatment
      of cystic fibrosis as its mucolytic action can prevent lung function deterioration by owering
      airways infections.

      RACONA study will test the hypothesize that nafamostat is useful in COVID-19 lung involvement
      because COVID-19 entails activation of the coagulation cascade, pulmonary embolism, and
      bacterial superinfections.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double blind, placebo-controlled parallel-group trial, on top of best standard of care</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Randomization will be done with an algorithm tailored to the study design. Investigators and patients will be blinded to the treatment administered.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time-to-clinical improvement</measure>
    <time_frame>day 1 until day 28</time_frame>
    <description>Time-to-clinical improvement (time from randomization to an improvement of two points (from the status at randomization) on a 7 category ordinal scale or live discharge from the hospital, whichever came first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responders</measure>
    <time_frame>day 1 until day 28</time_frame>
    <description>Rate of patients showing improvement of 2 points in 7 category ordinal scale (with 7 points the worst)(PubMed ID: 32187464)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Critical or dead patients</measure>
    <time_frame>day 1 until day 28</time_frame>
    <description>Proportion of patients who will progress to critical illness/death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pO2/FiO2 ratio</measure>
    <time_frame>day 1 until day 28</time_frame>
    <description>Change in pO2/FiO2 ratio over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score over time</measure>
    <time_frame>day 1 until day 28</time_frame>
    <description>Change Sequential organ failure assessment score (SOFA score) over time. The Score ranges from 0 to 24 (with 24 the worst)(PubMed ID: 11594901)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>day 1 until day 28</time_frame>
    <description>Duration of hospitalization in survivors (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation</measure>
    <time_frame>day 1 until day 28</time_frame>
    <description>Number of patients who require ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation duration</measure>
    <time_frame>day 1 until day 28</time_frame>
    <description>Duration of ventilation (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular disease</measure>
    <time_frame>day 1 until day 28</time_frame>
    <description>Proportion of patients who develop arrhythmia, or myocardial infarction, or other cardiovascular disease not present at the baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>COVID19</condition>
  <arm_group>
    <arm_group_label>Nafamostat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nafamostat mesylate on top of best standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo on top of best standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nafamostat Mesilate</intervention_name>
    <description>administered intravenously as a continuous infusion</description>
    <arm_group_label>Nafamostat</arm_group_label>
    <other_name>no alternative name. Commercial brands are available.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>administered intravenously as a continuous infusion</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>no alternative name.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized, COVID-19 positive, between 18 and ≤ 85 years of age;

          -  Signed Inform Consent Form;

          -  Body temperature &gt; 37.3 ℃;

          -  Oxygenation criterion (any of the following): i) Oxygen saturation ≤94% on Room Air;
             ii) PaO2/FiO2 ratio ≤300 mmHg but &gt; 100 mmHg, if patient on supplemental oxygen; iii)
             SpO2/FiO2&lt;200 if no arterial blood gas available;

          -  Respiratory rate (RR) ≥ 25 beats/min.

        Exclusion Criteria:

          -  Pregnant or lactating females;

          -  Unwillingness or inability to complete the study.

          -  Rapidly deteriorating clinical condition or low likelihood to complete the study
             according to the investigator;

          -  eGFR &lt; 30 ml/min/m2 assessed with CKD EPI formula;

          -  Current or chronic history of liver disease (Child Pugh score ≥ 10), or known hepatic
             or biliary abnormalities;

          -  Participation in a clinical trial with an investigational product within the following
             time period prior to the first dosing day in the current study: 5 half-lives or twice
             the duration of the biological effect of the investigational product (whichever is
             longer);

          -  Patients requiring high doses of loop diuretics (i.e. &gt; 240 mg furosemide daily) with
             significant intravascular volume depletion, as assessed clinically;

          -  History of allergy;

          -  History of sensitivity to heparin or heparin-induced thrombocytopenia;

          -  Unstable hemodynamics in the preceding 4 hours (SBP &lt; 90 mmHg, and/or vasoactive
             agents required);

          -  Hemoglobin &lt; 7 at time of drug infusion. Transfusion is allowed to increase hemoglobin
             levels before entry into the study;

          -  Malignancy or any other condition for which estimated 6-month mortality &gt;50%;

          -  Arterial blood pH less than 7.2;

          -  Known evidence of chronic interstitial infiltration at imaging;

          -  Known hospitalization within the past six months for respiratory failure (PaCO2 &gt; 50
             mmHg or PaO2 &lt; 55 mmHg, or oxygen saturation &lt;88% on FiO2 = 0.21);

          -  Known chronic vascular disease resulting in severe exercise restriction (i.e. unable
             to perform household duties);

          -  Known secondary polycythemia, severe pulmonary hypertension, or ventilator dependency;

          -  Known vasculitis with diffuse alveolar hemorrhage;.

          -  Pre-existing renal failure on hemodialysis or peritoneal dialysis requiring renal
             replacement therapy;

          -  Extracorporeal membrane oxygenation (ECMO);

          -  Immunosuppressive treatment;

          -  Patient in trials for COVID-19 within 30 days before;

          -  Unstable hemodynamics in the preceding 4 hours (MAP ≤ 65 mmHg, or SAP &lt; 90 mmHg, DAP &lt;
             60 mmHg, and vasoactive agents required);

          -  Hyperkalemia , i.e. serum K+ levels &gt; 5.0 mEq/L;

          -  Severe active bleeding;

          -  Any other uncontrolled comorbidities that increase the risks associated with the study
             drug administration, as assessed by the medical expert team.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gian Paolo Rossi, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Padova, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gian Paolo Rossi</last_name>
    <phone>00390498217821</phone>
    <phone_ext>2279</phone_ext>
    <email>gianpaolo.rossi@unipd.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gian Paolo Rossi, Prof.</last_name>
    <phone>00390498217821</phone>
    <phone_ext>2279</phone_ext>
    <email>gianpaolo.rossi@unipd.it</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Yamamoto M, Matsuyama S, Li X, Takeda M, Kawaguchi Y, Inoue JI, Matsuda Z. Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay. Antimicrob Agents Chemother. 2016 Oct 21;60(11):6532-6539. doi: 10.1128/AAC.01043-16. Print 2016 Nov.</citation>
    <PMID>27550352</PMID>
  </results_reference>
  <results_reference>
    <citation>Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.</citation>
    <PMID>32142651</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038.</citation>
    <PMID>32171076</PMID>
  </results_reference>
  <results_reference>
    <citation>Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.</citation>
    <PMID>32187464</PMID>
  </results_reference>
  <results_reference>
    <citation>Minakata D, Fujiwara SI, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Ochi SI, Nagayama T, Mashima K, Umino K, Nakano H, Yamasaki R, Morita K, Kawasaki Y, Sugimoto M, Yamamoto C, Ashizawa M, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Ohmori T, Kanda Y. Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies. Int J Hematol. 2019 Feb;109(2):141-146. doi: 10.1007/s12185-018-02567-w. Epub 2018 Dec 8.</citation>
    <PMID>30536180</PMID>
  </results_reference>
  <results_reference>
    <citation>Yu G, Li S, Wan R, Wang X, Hu G. Nafamostat mesilate for prevention of post-ERCP pancreatitis: a meta-analysis of prospective, randomized, controlled trials. Pancreas. 2015 May;44(4):561-9. doi: 10.1097/MPA.0000000000000310.</citation>
    <PMID>25822153</PMID>
  </results_reference>
  <results_reference>
    <citation>Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001 Oct 10;286(14):1754-8.</citation>
    <PMID>11594901</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 3, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2020</study_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Padova</investigator_affiliation>
    <investigator_full_name>Gian Paolo Rossi, MD, FAHA, FACC</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>Nafamostat</keyword>
  <keyword>proteases</keyword>
  <keyword>TMPRSS2</keyword>
  <keyword>covid-19</keyword>
  <keyword>coronavirus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nafamostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>GPR (PI)</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://ncov.medsci.ox.ac.uk</doc_url>
      <doc_comment>The link https://ncov.medsci.ox.ac.uk allows connection to EDCap database, a secure web platform for building and managing online databases and surveys. Data collection will use the WHO Case Record Form.</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

